Can-Fite BioPharma (CANF) reports Brazilian sexual dysfunction patent

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. filed a Form 6-K as a foreign private issuer describing a recent corporate update. The company reports that on December 26, 2025 it issued a press release titled “Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction,” highlighting patent protection in Brazil for a sexual dysfunction treatment.

The press release is furnished as Exhibit 99.1 and is incorporated by reference into Can-Fite’s existing shelf and employee benefit plan registration statements on Forms S-8 and F-3, making the patent-related disclosure part of those securities offering documents.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of December 2025

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

The press release attached hereto as Exhibit 99.1 is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384 and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000 and 333-281872), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On December 26, 2025, Can-Fite BioPharma Ltd. issued a press release entitled “Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction.” A copy of this press release is furnished herewith as Exhibit 99.1.

1

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated December 26, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: December 29, 2025	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

3

FAQ

What did Can-Fite BioPharma Ltd. (CANF) disclose in this December 2025 Form 6-K?

Can-Fite BioPharma Ltd. disclosed that it issued a press release on December 26, 2025 titled “Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction,” and furnished this press release as Exhibit 99.1.

What patent-related development does Can-Fite (CANF) highlight in the filing?

The filing highlights that Can-Fite was granted a Brazilian patent for the treatment of sexual dysfunction, as described in the attached press release titled “Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction.”

How is the press release incorporated into Can-Fite BioPharma’s existing SEC registration statements?

The press release attached as Exhibit 99.1 is incorporated by reference into Can-Fite’s Registration Statements on Form S-8 and Form F-3, becoming part of those registration statements from the date this report is submitted, to the extent not superseded by later filings.

Which SEC registration forms are affected by this Can-Fite (CANF) Form 6-K?

The Form 6-K states that the Exhibit 99.1 press release is incorporated by reference into Can-Fite’s Registration Statements on Form S-8 and on Form F-3 identified by their respective file numbers.

Who signed the Can-Fite BioPharma Ltd. December 2025 Form 6-K?

The report was signed by Motti Farbstein, who is identified as Can-Fite BioPharma Ltd.’s Chief Executive Officer and Chief Financial Officer.

What is Exhibit 99.1 in Can-Fite BioPharma’s December 2025 Form 6-K?

Exhibit 99.1 is the press release dated December 26, 2025 titled “Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction.”